GLP-1 pill vs injection
Direct answer
What you need to know
Evidence strength: ModerateBoth are real. The injections lead on results, the tablets on price. In their pivotal trials the weekly injections produced larger mean weight reductions than the tablets. But the lowest published self-pay price for any FDA-approved GLP-1 belongs to a tablet, at $149 a month. Neither format is a lesser version of the other — they are different products with their own trials.
Key takeaways
- Three approved tablets and five approved injectables; all are prescription-only.
- Injections led on mean weight reduction in trials — but those are separate trials.
- Both products tied for the cheapest published self-pay price are tablets, not injections.
- A medication you keep taking beats one you abandon, whichever way it goes in.
Important limitation: The figures below come from separate trials with different populations and durations. A difference between two trials is weaker evidence than a difference measured within one, and none of these products has been tested head-to-head against another format.
Next action: If needles are the obstacle, say so before ruling the class out — the tablets are a genuine option, not a consolation. Format availability by provider is in our directory.
Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration
General education, not medical advice. We do not publish dosing instructions — follow the label on your own prescription.
On results
| Product | Format | Weight reductionmean, headline dose |
|---|---|---|
| Semaglutide (Wegovy) | Injection | 14.9% |
| Tirzepatide (Zepbound) | Injection | 22.5% |
| Oral semaglutide (Wegovy pill) | Tablet | 13.6% |
| Orforglipron (Foundayo) | Tablet | 12.4% |
The ordering is consistent enough to be worth acting on: the injections are ahead. But the gap between the best tablet and the weekly semaglutide injection is smaller than the gap between the two injections, which is a useful thing to notice before treating “injection” as a single category.
One caution about reading a table of means and ordering yourself against it: the spread within each of those trials is far wider than the differences between them, so the ordering that holds for the groups need not hold for any one person. We show the distribution behind both averages, with the placebo arm alongside.
On price
This is where the ordering reverses. Wegovy tablets bought direct from the manufacturer are $149 a month — half the published self-pay price of the same drug in a pen, and — tied with Foundayo’s tablet at the same $149 — the lowest published price for any approved product in the class. The full comparison, including telehealth memberships added to medication prices, is on the cheapest way to get a GLP-1.
Two things about that reversal are worth being precise about. It applies to one molecule: semaglutide is the only GLP-1 with an approved tablet, so a reader comparing formats for tirzepatide has no equivalent choice to make — every approved tirzepatide is an injection. And it has a date on it, because the tier covering the 4 mg dose is stated to rise at the end of August 2026. Both are set out with the provider figures in what semaglutide costs in each of its forms.
The injection wins on the trial numbers and loses on the price. Which of those two facts matters more is a question about your circumstances, not about the drugs.
The differences nobody puts in the comparison
- Frequency. The injections are weekly; the tablets are daily. A weekly injection is four doses a month to remember, against thirty.
- Timing rules. The peptide tablets ask for an empty stomach and a waiting window; the non-peptide tablet does not, and the injections are indifferent to food. See the pill page for why.
- The device. Among injections, whether you get a multi-dose pen, a single-dose pen, or a vial changes the price and, on Medicare, the coverage — see the shot page.
- What you will keep doing. Persistence is the variable that decides outcomes over a year, and it is the one no trial table captures.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved dosage forms, dosing frequency, and administration instructions for the products compared.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and dosage form for each product, checkable in Drugs@FDA.
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of MedicineSupports: The 14.9% mean body-weight reduction reported for Semaglutide (Wegovy) in STEP 1, NEJM 2021 · N=1,961 · 68 weeks.
- Lilly's SURMOUNT-1 Results Published in New England Journal of MedicineEli Lilly (investor release citing NEJM)Supports: The 22.5% mean body-weight reduction reported for Tirzepatide (Zepbound) in SURMOUNT-1, NEJM 2022 · N=2,539 · 72 weeks.
- FDA Approves Oral Wegovy: OASIS 4 Trial ResultsApplied Clinical Trials OnlineSupports: The 13.6% mean body-weight reduction reported for Oral semaglutide (Wegovy pill) in OASIS 4 · N=307 · 64 weeks.
- Lilly's Oral GLP-1 Orforglipron Demonstrated Meaningful Weight LossEli LillySupports: The 12.4% mean body-weight reduction reported for Orforglipron (Foundayo) in ATTAIN-1 · N>3,100 · 72 weeks.
- Wegovy cost, coverage and savings informationNovoCare, Novo NordiskSupports: Self-pay pricing for Wegovy tablets and pens. Verified 2026-08-13.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.